Journal: Clinical and Translational Medicine

Article Title: Muscle‐specific gene editing improves molecular and phenotypic defects in a mouse model of myotonic dystrophy type 1

doi: 10.1002/ctm2.70227

Figure Lengend Snippet: Improvement of bone health and body composition parameters in MyoAAV–C3/384‐treated homozygous DMSXL mice. A group of DMSXL male and female homozygous mice at age P5 received a systemic injection of MyoAAV vectors carrying Cas9 and sgC3/384 pair ( n = 7), and underwent whole‐body DEXA analysis at 16 weeks of age. Control animals were wild‐types (WT, n = 16) and untreated DMSXL homozygous mice (NT, n = 14) of both sexes. All data are represented as mean ± SEM and individual data points; data from male (open symbols) and female (filled symbols) mice are pooled. (A–C) Bone health parameters: bone mineral density (BMD) (A), bone mineral content (BMC) (B) and bone area (C). (A) BMD: MyoAAV–C3/384 vs. NT, unpaired t ‐test with Welch's correction, t = 2.595, df = 14, * p = .02. (B) BMC: MyoAAV–C3/384 vs. NT, unpaired t ‐test with Welch's correction, t = 3.371, df = 15, ** p = .004. (C) Bone area, WT vs. NT, Mann–Whitney test, U = 53, * p = .013; MyoAAV–C3/384 vs. NT, unpaired t ‐test with Welch's correction, t = 4.25, df = 16, *** p = .0006. (D–F) Body composition parameters: fat tissue percentage (D), lean tissue percentage (E) and fat/lean mass ratio (adiposity index, F). (D) Fat tissue %: WT vs. NT, Mann–Whitney test, U = 46, ** p = .0052; MyoAAV–C3/384 vs. NT, unpaired t ‐test with Welch's correction, t = 2.684, df = 17.14, * p = .015. (E) Lean tissue %: WT vs. NT, Mann–Whitney test, U = 45, ** p = .0045; MyoAAV–C3/384 vs. NT, unpaired t ‐test with Welch's correction, t = 2.684, df = 17.14, * p = .015. (F) Adiposity index, WT vs. NT, unpaired t ‐test with Welch's correction, t = 3.265, df = 15.37, ** p = .0051; MyoAAV–C3/384 vs. NT, unpaired t ‐test with Welch's correction, t = 2.643, df = 16.41, * p = .017.

Article Snippet: Bone health and body composition were comprehensively evaluated at the age of 4 months using Dual Energy X‐ray Absorptiometry (DEXA) analyser (The PARAMETER™ XPERT® 40 Cabinet X‐ray System, T00261_A 9.2019; Kubtec Scientific, 111 Research Drive Stratford, CT 06615, USA).

Techniques: Injection, Control, MANN-WHITNEY

Journal: Blood Advances

Article Title: Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model

doi: 10.1182/bloodadvances.2025017296

Figure Lengend Snippet: Small animal [ 89 Zr]-DFO-daratumumab confirms absence of hCD38 expression in vivo in MM.1S WT cells. (A) Cell binding of [ 89 Zr]-DFO-daratumumab to a murine MM cell line with hCD38 expression knocked in (5TGM1-hCD38-KI cells). (B) Representative 30-minute static PET/CT scans of MM.1S WT and MM.1S CD38 KO tumor bearing mice at 3 and 6 days after injection of [ 89 Zr]-DFO-daratumumab. Areas of high tracer uptake in the bones are indicated by white arrows. (C) Comparative quantification of SUV max between WT and CD38 KO tumor bearing mice at 6 days post-injection of [ 89 Zr]-DFO-daratumumab (2-way ANOVA; ns P > .05; ∗∗∗∗ P < .001). (D) Comparative quantification of the tissue density (Hounsfield units, HU) from in vivo CT across corresponding bone ROIs in MM.1S WT and MM.1S CD38 KO tumor bearing mice (2-way ANOVA; ns P > .05; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .005; ∗∗∗∗ P < .001). (E) Comparative quantification of the BMD (milligram per square centimeter) of each bone ROI using DEXA imaging between MM.1S WT and MM.1S CD38 KO tumor bearing mice (2-way ANOVA; ns P > .05; ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .001). (F) Planar X-ray images of the femur and tibia from mice implanted with WT and CD38 KO MM cells reveal potential osteolytic lesions of the cortical and trabecular bone, marked by white arrows, indicating areas of bone degradation.

Article Snippet: Ex vivo dual-energy X-ray absorptiometry (DEXA) was performed using a Faxitron UltraFocus100 system.

Techniques: Expressing, In Vivo, Binding Assay, Positron Emission Tomography-Computed Tomography, Injection, Imaging